Literature DB >> 3159752

A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.

F B Waldo, J Forristal, L Beischel, C D West.   

Abstract

C3 nephritic factor (C3NeF) was used to assess the formation of the fluid-phase amplification convertase, C3b,Bb, in 37 serum specimens from 24 patients with systemic lupus erythematosus (SLE). C3b,Bb formation was measured by the concentration of Ba, released when C3b,B is activated. Incubation of normal human serum (NHS) with C3NeF accelerates C3b amplification loop turnover with the formation of large quantities of C3b,Bb. In contrast, sera from 22 of 24 patients with SLE formed little or no convertase when incubated with C3NeF. C3 conversion to C3b was commensurately reduced. The inhibition could not be attributed to depressed serum concentrations of C3, factor B, or classical pathway components. Inhibitor present in excess could be demonstrated in 23 of 34 specimens of SLE serum by mixing experiments. The spontaneous convertase formation that occurs when a portion of the serum H is inactivated with F(ab')2 anti-H was also shown to be inhibited in SLE serum. The inhibition was found, however, to be H dependent in that convertase formation was normal in SLE serum depleted of H. It is concluded that the C3b in most SLE sera is unusually susceptible to inactivation by H, but a functional abnormality was not demonstrable in either C3 or H isolated from SLE serum. The inhibition could be simulated in NHS by addition of heparin, 100 micrograms/ml. In vivo, inhibition of convertase formation could interfere with the solubilization and disposal of immune complexes by reducing the deposition of C3b on the immune complex lattice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159752      PMCID: PMC425533          DOI: 10.1172/JCI111891

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

2.  C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b.

Authors:  C Mold; M Kingzette; H Gewurz
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

3.  Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.

Authors:  M Takahashi; S Takahashi; V Brade; V Nussenzweig
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

4.  The role of complement in the binding and degradation of immunoglobulin aggregates by macrophages.

Authors:  A Kijlstra; L A van Es; M R Daha
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

5.  The alternative pathway C3/C5 convertase: chemical basis of factor B activation.

Authors:  P H Lesavre; T E Hugli; A F Esser; H J Müller-Eberhard
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

6.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

7.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

8.  The effect of complement on the ingestion of soluble antigen-antibody complexes and IgM aggregates by mouse peritoneal macrophages.

Authors:  J L van Snick; P L Masson
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

9.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  5 in total

Review 1.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

2.  Lack of complement activation by human IgA immune complexes.

Authors:  H Imai; A Chen; R J Wyatt; A Rifai
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

3.  A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1).

Authors:  Y C Ng; D K Peters; S A Cederholm-Williams; M J Walport
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

4.  Immune adherence and clearance of hepatitis B surface Ag/Ab complexes is abnormal in patients with systemic lupus erythematosus (SLE).

Authors:  N Madi; G Steiger; J Estreicher; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

Review 5.  Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations.

Authors:  Fernando Corvillo; Marcin Okrój; Pilar Nozal; Marta Melgosa; Pilar Sánchez-Corral; Margarita López-Trascasa
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.